- Home
- TOYO vs ACRS Comparison
TOYO vs ACRS Comparison
Compare TOYO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- ACRS
- Stock Information
- Founded
- TOYO 2022
- ACRS 2012
- Country
- TOYO Japan
- ACRS United States
- Employees
- TOYO 528
- ACRS 64
- Industry
- TOYO
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- ACRS Health Care
- Exchange
- TOYO NYSE
- ACRS Nasdaq
- Market Cap
- TOYO 153.8M
- ACRS 137.5M
- IPO Year
- TOYO N/A
- ACRS 2015
- Fundamental
- Price
- TOYO $3.53
- ACRS $1.46
- Analyst Decision
- TOYO
- ACRS Strong Buy
- Analyst Count
- TOYO 0
- ACRS 8
- Target Price
- TOYO N/A
- ACRS $9.71
- AVG Volume (30 Days)
- TOYO 18.9K
- ACRS 709.4K
- Earning Date
- TOYO 05-15-2025
- ACRS 05-08-2025
- Dividend Yield
- TOYO N/A
- ACRS N/A
- EPS Growth
- TOYO 350.49
- ACRS N/A
- EPS
- TOYO 1.09
- ACRS N/A
- Revenue
- TOYO $176,957,128.00
- ACRS $17,777,000.00
- Revenue This Year
- TOYO N/A
- ACRS N/A
- Revenue Next Year
- TOYO N/A
- ACRS $14.59
- P/E Ratio
- TOYO $3.25
- ACRS N/A
- Revenue Growth
- TOYO 183.69
- ACRS N/A
- 52 Week Low
- TOYO $1.36
- ACRS $0.99
- 52 Week High
- TOYO $8.34
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- ACRS 61.33
- Support Level
- TOYO N/A
- ACRS $1.22
- Resistance Level
- TOYO N/A
- ACRS $1.56
- Average True Range (ATR)
- TOYO 0.00
- ACRS 0.09
- MACD
- TOYO 0.00
- ACRS 0.03
- Stochastic Oscillator
- TOYO 0.00
- ACRS 75.00
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries, is engaged in research and development, production, and sales of solar cells. Geographically, the company generates revenue from Asia and the USA, out of which the majority of revenue is generated from Asia.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.